UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.

UBS analyst Michael Yee called Novo Nordisk a value trap, but still sees a turnaround playing out over time.

CryptoAlerta — análise de criptomoedas e mercado em tempo real